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(COPD) became popular, it has been commonly, 
yet incorrectly, viewed solely as a COPD pheno‑
type and hence rarely diagnosed in individuals 
without COPD. In fact, CB is common in the gen‑
eral population, including people over 40 years 
of age as well as younger ones, many of whom do 
not have COPD.4-7 Contrary to older reports,8,9 
the results of recent longitudinal studies sug‑
gest that CB symptoms in the general popula‑
tion are associated with an increased rate of lung 
function decline as well as a higher risk of COPD 
INTRODUCTION Chronic cough and sputum pro‑
duction are among the most commonly reported 
medical symptoms.1 Cough and sputum expecto‑
ration for most days for at least 3 months dur‑
ing at least 2 consecutive years are considered 
the epidemiological criteria of chronic bronchi‑
tis (CB).2 Clinical diagnosis requires exclusion of 
common diseases causing CB symptoms, espe‑
cially asthma and heart failure. CB was originally 
recognized as a stand ‑alone condition,3 but since 
the term chronic obstructive pulmonary disease 
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INTRODUCTION Chronic bronchitis (CB) symptoms are commonly reported in individuals without chronic 
obstructive pulmonary disease (COPD), but CB is rarely diagnosed in this population.
OBjECTIvEs We aimed to determine the prevalence and burden of CB, as well as its risk factors, in 
a population of patients without COPD.
PATIENTs AND mEThODs Data from the “Health Action” program (a lung cancer prevention and health 
care improvement program conducted in Proszowice County, Poland) were used. All county inhabitants 
aged 40 years or older without COPD were invited to participate. As part of the program, a questionnaire 
was administered to assess CB symptoms and risk factors. Spirometry at baseline and after the bron-
chodilator test was also performed.
REsULTs CB symptoms were present in 9.1% of the 3558 participants. The prevalence of CB in the study 
population was 7.12% (95% CI, 6.70–7.56). Patients with CB had more dyspnea and more often received 
medical treatment for lung disease or were hospitalized for respiratory disorders than patients without 
CB. CB was associated with worse lung function and a worse score in the modified Medical Research 
Council Dyspnea Scale even after adjustment for possible confounders. In a multivariate analysis, male 
sex, age over 70 years, current smoking, passive exposure to tobacco smoke, gas or wood heating, 
occupational exposure to chemical agents, lower forced expiratory volume in 1 second, and asthma 
correlated with an increased risk of CB.
CONCLUsIONs CB symptoms are common in individuals without COPD aged 40 years or older and are 
associated with more dyspnea irrespective of lung function and comorbidities.
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for at least 2 years. Asthma and other medical 
diagnoses were assessed based on self ‑reported 
previous medical diagnoses.
statistical analysis Within ‑group comparisons 
were made using the χ2 test and the t test or 
the Mann–Whitney test, as appropriate. Regres‑
sion analysis was used to evaluated the relation‑
ship of CB symptoms with specific negative out‑
comes. Postbronchodilator FEV1, FVC, FEV1/FVC, 
and mMRC Dyspnea Scale score were used as de‑
pendent variables in separate regression mod‑
els, along with CB, sex, age, smoking status, and 
self ‑reported asthma (and FEV1 in a model with 
the mMRC Dyspnea Scale score as a dependent 
variable) as potential predictors. Multiple logistic 
regression was used to assess potential risk factors 
for CB symptoms. The presence of CB symptoms 
was used as a dependent variable. The following 
parameters were used as independent variables: 
age, sex, education, smoking status, e ‑cigarette 
use (vaping), exposure to passive smoke, occupa‑
tional exposure (working in mining and metallur‑
gy industry, welding, farming, using pesticides or 
fertilizers during farm work, exposure to chemical 
agents), household heating (with coal, coke gas, or 
wood), household cooking (using gas oven, electric 
oven, or wood or coal stove), self ‑reported med‑
ical diagnoses of asthma and bronchiectasis, as 
well as postbronchodilator lung function (FEV1). 
All the above analyses were repeated after exclud‑
ing asthma ‑reporting participants from the data‑
set. Similarly, risk factor analysis was repeated af‑
ter excluding asthma ‑reporting participants from 
the dataset, and it was carried out separately in 
nonsmoking individuals without asthma. All anal‑
yses were performed with R statistical software, 
version 3.3.1 (https://www.R ‑project.org). The re‑
sults with a P value of less than 0.05 were consid‑
ered significant.
REsULTs Approximately 70% of county inhabit‑
ants aged 40 years or older gave their consent to 
participate in the study. Good ‑quality question‑
naire data were obtained from 14 323 respondents 
(98.4%), and appropriate ‑quality prebronchodi‑
lator and postbronchodilator spirometry data, 
from 4105 respondents (~20%). Based on post‑
bronchodilator spirometry, COPD was excluded 
in 3558 of participants (86.7%). All these indi‑
viduals were subjected to further analyses, unless 
stated otherwise, as outlined in FIGURE 1.
CB symptoms were present in 9.1% of respon‑
dents (n = 323), whereas chronic cough and chron‑
ic sputum production, in 16% (n = 569) and 10.6% 
(378), respectively. The prevalence of CB symp‑
toms decreased to 7.6% (n = 271) after exclusion 
of individuals who reported asthma diagnosis. CB 
symptoms were present in 1.6% of lifetime non‑
smokers without asthma (n = 57). The popula‑
tion prevalence of CB symptoms was estimated 
at 7.12% (95% CI, 6.70–7.56) in the whole stud‑
ied population and 6.31% (95% CI, 5.9–6.74) in 
those without asthma.
and death.10-12 It has been suggested that in pa‑
tients with normal lung function CB symptoms 
may also be associated with worse quality of life 
as well as an increased risk of lung function im‑
pairment and respiratory exacerbations.4 Howev‑
er, this issue has not received adequate attention 
in clinical practice or scientific research.
Recently, a large health promotion program 
has been implemented in Proszowice County in 
southern Poland, aiming to improve the respi‑
ratory health status of the local population.13 
The program consisted of a series of educational 
initiatives and active prevention measures aimed 
at identification of individuals with respirato‑
ry symptoms among the county population. We 
have used the data from this program to deter‑
mine the prevalence and burden of CB symptoms, 
as well as their risk factors, in a population of pa‑
tients without irreversible airway obstruction.
PATIENTs AND mEThODs We used data from “Ac‑
tion Health,” a health program promoting lung 
cancer prevention and health care improvement 
implemented in Proszowice County, Poland, be‑
tween 2014 and 2016. The details and main re‑
sults of the program were published elsewhere.13 
In brief, all county inhabitants aged 40 years or 
older were invited to participate. The program 
was based on a questionnaire composed of ques‑
tions on respiratory symptoms (including detailed 
questions on cough and sputum production as 
well as the modified Medical Research Council 
[mMRC] Dyspnea score), previous medical di‑
agnoses, and exposure to known and potential 
respiratory risk factors (including occupational 
risk factors). The questionnaires were adminis‑
tered at participants’ homes by trained staff su‑
pervised by the medical coordinator of the pro‑
gram (WS). Questionnaire data were analyzed 
based on prespecified rules. Individuals with re‑
spiratory symptoms or exposure to risk factors 
or both were offered spirometry, chest x ‑ray, and 
further diagnostic management, as clinically in‑
dicated, at a respiratory clinic at County Hospi‑
tal in Proszowice. Spirometry was performed in 
the office by experienced technicians, using Lung‑
Test 1000 spirometers (MES, Kraków, Poland), 
before and after bronchodilator administration 
(400 µg of inhaled salbutamol). All spirometry 
results were reviewed by the medical coordina‑
tor (WS), and those of acceptable quality were in‑
cluded in further analyses.14 COPD was excluded 
based on the postbronchodilator ratio of forced 
expiratory volume in 1 second (FEV1) to forced ex‑
piratory capacity (FVC) equal to or higher than 
the lower limit of normal.15 CB symptoms were 
considered to be present when a participant: 1) 
provided affirmative answer to the following 
questions on chronic cough and chronic sputum 
production: “Do you cough for most days for 
at least 3 month each year?” and “Do you cough 
up phlegm on most days for at least 3 months 
each year?”; and 2) confirmed that both chron‑
ic cough and chronic sputum production lasted 
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FIGURE 1 Flowchart for selection of study participants 
Abbreviations: CB, chronic bronchitis; COPD, chronic obstructive pulmonary disease
Total county population aged 40 or older 
n = 20 700
Spirometry performed  
n = 5816
Good quality questionnaire data 
n = 14 323
COPD excluded based on post- 
bronchodilator spirometry data 
n = 3558
Questionnaire data available 
n = 14 555
Good-quality spirometry data available 
n = 4105
Referred for spirometry 
n = 6420
Referred for spirometry 
n = 6420
CB symptoms present 
n = 323
CB symptoms absent 
n = 3235
CB symptoms present after exclusion 
of persons reporting asthma diagnosis 
n = 271
Refused to participate/untraceable/ 
no contact 
n = 6205 
Poor-quality spirometry data  
n = 348 
Data not available in an electronic form 
(random files corrupted) 
n = 1363 
Resigned/refused 
n = 604
No respiratory symptoms,  
no exposure to known 
respiratory risk factors 
n = 7903
Low-quality questionnaire  
data 
n = 232
COPD diagnosed based on 
postbronchodilator spirometry 
n = 547
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even after asthma ‑reporting participants were ex‑
cluded from the analyses. Furthermore, associa‑
tions of CB symptoms with a lower FEV1/FVC ra‑
tio and a worse mMRC Dyspnea Scale score were 
still significant after adjustment for possible con‑
founders including sex, age, asthma, and smok‑
ing (and lung function in the case of the mMRC 
Dyspnea Scale score) (TABLE 3).
A previous medical diagnosis of CB was re‑
ported in 155 participants (4.4% of the total 
The characteristics of participants differed sig‑
nificantly between those with and without CB 
symptoms. Individuals with CB symptoms were 
more often male, smokers, less educated, and di‑
agnosed with airway disorders (TABLE 1). Moreover, 
compared with participants without CB, those 
with CB more often had dyspnea, worse lung 
function, and more often received medical care 
for lung disease, including inpatient treatment 
(TABLE 2). These differences remained significant 
TABLE 1 Comparison of demographic characteristics between the study groups (total population and participants with and without chronic 
bronchitis symptoms)
Parameter Total population  
(n = 3558)
No CB symptoms  
(n = 3235)
CB symptoms  
(n = 323)
P value
CB vs no CB
Age, y, mean (SD) 58.6 (10.8) 58.5 (10. 9) 59.7 (10.7) 0.06
Women, % (n) 52.1 (1852) 53.8 (1739) 35.0 (113) <0.01
Education, % (n) ≤8 years (primary 
school)
48.5 (1726) 49.3 (1540) 58.49 (186) 0.01
9–12 years (high 
school)
41.7 (1483) 43.79 (1368) 36.16 (115)
>12 years (university) 6.6 (233) 6.91 (216) 5.35 (17)
Smoking, % (n) Lifetime nonsmokers 44.7 (1591) 47.4 (1516) 23.4 (75) <0.01
Previous smokers 30.4 (1082) 31.2 (999) 25.9 (83)
Current smokers 23.7 (845) 21.4 (683) 50.6 (162)
Current passive exposure to tobacco smoke, % (n) 21.3 (757) 20.8 (668) 27.7 (89) 0.04
Diagnosed asthma, % (n) 7.6 (270) 6.7 (218) 16.1 (52) <0.01
Diagnosed chronic airway disease (asthma, COPD, 
emphysema), % (n)
9.5 (339) 8.2 (264) 23.2 (75) <0.01
Abbreviations: see FIGURE 1
TABLE 2 Comparison of dyspnea rates, lung function, and medical history between the study groups (total population and participants with and 
without chronic bronchitis symptoms)
Parameter Total population  No CB symptoms  CB symptoms  P value
Total population n = 3558 n = 3235 n = 323 CB vs no CB
Dyspnea, % (n) 30.4 (1083) 27.5 (889) 60.1 (194) <0.01
mMRC Dyspnea Scale score, points, median (IQR) 0.0 (1.0) 0.0 (0.0) 1.0 (4.0) <0.01
Lung functiona, mean (SD) FEV1 103.2 (17.0) 103.5 (17.0) 100.1 (17.5) 0.01
FVC 107.0 (17.2) 107.2 (17.1) 105.4 (18.0) 0.06
FEV1/FVC 79.0 (6.3) 79.2 (6.2) 76.8 (6.1) <0.01
Medical therapy for lung disease, % (n) 7.3 (261) 6.0 (195) 20.4 (66) <0.01
No. of hospitalizations for respiratory disorders 
in the previous year, median (IQR)
0.0 (0.0) 0.0 (0.0) 0.0 (0.0) <0.01
After exclusion of asthma-reporting particpants n = 3288 n = 3017 n = 271 CB vs no CB
Dyspnea, % (n) 26.6 (873) 24.1 (727) 53.9 (146) <0.01
mMRC Dyspnea Scale score, points, median (IQR) 0.0 (0.0) 0.0 (0.0) 0.0 (3.0) <0.01
Lung functiona, mean (SD) FEV1 103.8 (16. 8) 104.0 (16.8) 101.7 (16.5) 0.03
FVC 107.3 (17.0) 107.4 (17.0) 106.4 (17.3) 0.38
FEV1/FVC 72.2 (6.2) 79.4 (6.2) 77.3 (6.0) <0.01
Medical treatment for lung disease, % (n) 1.7 (57) 1.2 (36) 7.7 (21) <0.01
Number of hospitalizations for respiratory disorders 
in the previous year, median (IQR)
0.0 (0.0) 0.0 (0.0) 0.0 (0.0) <0.01
a postbronchodilator, expressed as % of predicted values
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; mMRC, modified Medical Research Council; others, see 
FIGURE 1
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The prevalence of CB in the general population or 
individuals without COPD in most reports falls in 
the approximate range of 3% to 11%.4,6,17-20 Even 
in younger adults (20–44 years old), the CB prev‑
alence rates were reported to range from 0.7% 
to 9.7% in a multicenter study.5 High prevalence 
of CB symptoms in people without COPD seems 
alarming, considering that: 1) they are at an in‑
creased risk of COPD10-12; 2) there is consistent 
research evidence to support a significant CB‑
‑related burden also in individuals with normal 
lung function4,20,21; and 3) most of them remain 
undiagnosed.
The results of studies on CB prevalence depend 
on the definitions used. Clinically, CB is defined 
“by cough and sputum expectoration occurring 
on most days for at least 3 months of the year and 
for at least 2 consecutive years when other respi‑
ratory or cardiac causes for the chronic productive 
cough are excluded.”22 In epidemiological studies, 
the latter part of the definition is usually omit‑
ted,23 as clinical exclusion of underlying diseases 
is usually not feasible in the course of epidemio‑
logical studies, especially those dealing with large 
samples of subjects. Because asthma is the most 
common reason for reporting CB symptoms and 
is typically identified and self ‑reported by pa‑
tients, some authors decided to perform their 
analyses after exclusion of such individuals. We 
also adopted this approach in the present study 
and reported data based on the analysis of the to‑
tal sample as well as the population after exclu‑
sion of participants reporting asthma diagnosis.
We observed that CB symptoms were associ‑
ated with significantly worse lung function and 
more dyspnea as compared with CB ‑free popula‑
tion and the size effect was large. This relation‑
ship was independent of the presence of asth‑
ma or other confounders. This finding is in line 
with other reports that linked CB, even in the ab‑
sence of COPD, with a decreased quality of life.20,24 
No evidence ‑based medical interventions, ex‑
cept those aimed at smoking cessation, can be 
offered to these patients. However, it is impor‑
tant to identify these individuals because smok‑
ing cessation slows down lung function decline 
and may lead to resolution of CB (at least in some 
patients), and the proportion of smokers is still 
high in Poland despite the decrease observed in 
recent years.25 Unfortunately, only a very small 
percentage of participants reporting CB symp‑
toms were correctly diagnosed (<6% after exclu‑
sion of those reporting asthma diagnosis). This 
observation suggests that chronic cough with 
sputum production is overlooked or disregarded 
by patients and physicians.
The results of the risk factor analysis are 
mostly in keeping with previous evidence. 
Not surprisingly, current smoking was identi‑
fied as a risk factor for CB symptoms. Howev‑
er, only about 50% of individuals with CB in 
our sample were current smokers. This indi‑
cates that CB should not be viewed exclusive‑
ly as a “smoker’s disease.” In our sample, we 
population), including 24 participants (7.4%) 
reporting CB symptoms and 131 asymptomatic 
ones (4.1%). When individuals with asthma were 
excluded from the analysis, the percentage of par‑
ticipants reporting CB symptoms who were pre‑
viously diagnosed with CB was 5.95% (16 of 271).
In the multivariate analysis, male sex, age over 
70 years, current smoking, passive exposure to to‑
bacco smoke, household heating with gas or wood, 
occupational exposure to chemical agents, low‑
er FEV1, and asthma were associated with an in‑
creased probability of reporting CB symptoms 
(TABLE 4). When the analysis was repeated, taking 
also the number of cigarettes smoked daily into 
account, it did not reveal a significant effect of 
sex. When participants with asthma were exclud‑
ed from the multivariate analysis, current smok‑
ing, passive exposure to tobacco smoke, occupa‑
tional exposure to chemical agents, and house‑
hold heating with gas remained significantly asso‑
ciated with the risk of CB symptoms. In an analy‑
sis limited to nonsmokers without asthma, only 
household heating with gas and occupational ex‑
posure to chemical agents were associated with 
an increased risk of CB symptoms.
DIsCUssION Our findings indicate that CB 
symptoms are common in individuals without 
COPD aged 40 years or older. The estimated prev‑
alence of these symptoms in our study popula‑
tion was approximately 7%, and, importantly, 
most of the affected individuals did not have asth‑
ma. The estimated number of individuals affect‑
ed with CB symptoms in Poland is approximate‑
ly 2 million (more than 1.7 million after exclu‑
sion of those with asthma).16 Moreover, in pa‑
tients without COPD, CB symptoms were reported 
more often than asthma. Compared with oth‑
er reports, the proportion of patients with CB 
symptoms in our sample was in the upper range. 
TABLE 3 Relationship of chronic bronchitis with lung function parameters and mMRC 
Dyspnea Scale score in a multivariate analysis
Dependent variable Adjusted change in participants with CB 
vs those without CB (95% CI)a
P value
Total population (n = 3558)
FEV1, % pred. –1.85 (–3.82–0.12) 0.06
FVC, % pred. –0.89 (–2.9–1.12) 0.38
FEV1/FVC, % –0.75 (–1.41 to –0.09) 0.03
mMRC Dyspnea Scale 
score, points
0.81 (0.68–0.95)b <0.01
After exclusion of asthma-reporting particpants (n = 3288)
FEV1, % pred. –1.61 (–3.72–0.51) 0.14
FVC, % pred. –0.61 (–2.77–1.55) 0.58
FEV1/FVC ratio, % –0.73 (–1.44 to –0.02) 0.04
mMRC Dyspnea Scale 
score, points
0.75 (0.61–0.88)b <0.01
a Adjusted for sex, age, smoking status, and reported asthma diagnosis
b Adjusted for sex, age, smoking status, reported asthma diagnosis, and FEV1
Abbreviations: see FIGURE 1 and TABLE 2
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TABLE 4 Risk factors of chronic bronchitis in a multivariate analysis
Potential risk factor Total After excluding asthma -reporting 
participants
After excluding asthma -reporting 
participants and smokers
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Male sex 1.64 (1.22–2.21) 0.001 1.48 (1.07–2.04) 0.017 1.35 (0.86–2.11) 0.188
Age, y   30–49 Ref.
  50–59 1.31 (0.91–1.87) 0.147 1.25 (0.86–1.82) 0.243 1.14 (0.62–2.07) 0.68
  60–69 1.20 (0.83–1.74) 0.327 1.14 (0.77–1.68) 0.515 1.18 (0.66–2.12) 0.583
  ≥70 1.57 (1.02–2.44) 0.043 1.40 (0.86–2.28) 0.176 1.73 (0.92–3.25) 0.09
Education   University Ref.
  Below primary 2.35 (0.3–18.5) 0.417 2.18 (0.28–17.21) 0.461 – 0.983
  Primary 1.80 (0.23–14.23) 0.578 1.66 (0.21–13.23) 0.63 – 0.983
  High 1.57 (0.19–13.32) 0.678 1.58 (0.18–13.55) 0.677 – 0.983
Smoking status   Lifetime 
 nonsmokers
Ref.
  Former smokers 1.23 (0.86–1.75) 0.252 1.23 (0.83–1.83) 0.309 1.31 (0.86–1.99) 0.206
  Current smokers 4.38 (3.13–6.12) 0.001 4.53 (3.15–6.49) 0.001 NA NA
E -cigarette use 1.26 (0.8–1.98) 0.320 1.36 (0.86–2.16) 0.192 2.68 (0.74–9.71) 0.133
Exposure to tobacco smoke 1.47 (1.09–1.99) 0.013 1.48 (1.06–2.05) 0.021 1.55 (0.95–2.51) 0.078
Working for 
≥3 months
Coal mine 1.41 (0.58–3.43) 0.447 1.47 (0.56–3.86) 0.436 0.56 (0.07–4.69) 0.595
Steelworks 1.31 (0.83–2.08) 0.252 1.60 (0.99–2.57) 0.054 0.78 (0.30–2.01) 0.6
Welding industry 0.83 (0.51–1.36) 0.464 0.91 (0.54–1.55) 0.731 0.63 (0.25–1.55) 0.312
Farming 0.94 (0.63–1.4) 0.743 0.93 (0.61–1.43) 0.741 0.79 (0.43–1.44) 0.434
Occupational 
exposure
Pesticides or 
fertilizers
1.41 (1.00–2.01) 0.053 1.45 (0.98–2.14) 0.061 1.61 (0.94–2.75) 0.083
Asbestos 2.00 (0.68–5.84) 0.207 2.22 (0.74–6.62) 0.153 1.12 (0.12–10.34) 0.918
Chemical agents 1.56 (1.15–2.12) 0.004 1.67 (1.20–2.32) 0.002 1.99 (1.25–3.16) 0.004
Household 
heating
Coal 1.31 (0.67–2.54) 0.432 1.57 (0.73–3.37) 0.25 1.96 (0.68–5.59) 0.211
Coke 1.00 (0.22–4.5) 0.998 1.50 (0.34–6.72) 0.595 1.22 (0.16–9.37) 0.846
Gas 3.60 (1.83–7.08) <0.001 4.56 (2.10–9.92) 0.001 3.95 (1.38–11.28) 0.01
Wood 1.38 (1.04–1.84) 0.026 1.37 (1.00–1.87) 0.052 1.24 (0.80–1.91) 0.34
Cooking fuel Electric Ref.
Gas 1.09 (0.48–2.52) 0.832 0.91 (0.40–2.10) 0.832 1.40 (0.48–4.15) 0.54
Wood 1.07 (0.39–2.98) 0.892 0.98 (0.53–1.81) 0.951 0.98 (0.44–2.19) 0.965
Coal 1.30 (0.14–12.53) 0.821 1.19 (0.14–9.87) 0.874 3.34 (0.41–27.55) 0.262
Asthma 3.46 (2.39–5.01) <0.001 NA NA NA NA
Bronchiectasis 0.63 (0.08–5.27) 0.672 4.08 (0.42–39.78) 0.226 7.57 (0.73–79.01) 0.091
FEV1, per 10% decrease 1.08 (1.00–1.17) 0.040 1.07 (0.98–1.17) 0.118 1.08 (0.96–1.21) 0.226
Abbreviations: NA, not applicable; OR, odds ratio; Ref., reference; others, see TABLE 2
identified occupational exposure to chemical 
agents as a potential risk factor. Various other 
environmental factors were reported to be re‑
lated to an increased risk of CB,26-29 with long‑
‑term exposure to multiple inhaled smokes, va‑
pors, and particles likely to evoke CB symptoms. 
Surprisingly, we also observed a strong associ‑
ation between household heating with gas and 
an increased risk of CB. Such observations have 
been reported previously, yet the studies were 
carried out in other populations using different 
methods of gas heating.30 There is no clear bio‑
logical rationale for this finding, as households 
using gas for heating in the studied region are 
fitted with modern, low ‑emission, and hermetic 
gas boilers. Moreover, there was no association 
between using a gas oven for cooking (poten‑
tially linked to the exposure to gas combustion 
products) and the risk of CB symptoms. Local‑
ly, only relatively wealthy households can afford 
gas ‑powered heating installations, decreasing 
the odds that lower material status might play 
a role as a potential confounder. We hypothesize 
that household heating with gas may be related 
to building construction characteristics that alter 
the microclimate (increasing the temperature or 
decreasing the humidity) and slow down the air 
exchange rate inside the house. This appears to 
be supported by the fact that most local hous‑
es only have gravitational ventilation systems, 
and modern, typically gas ‑heated, buildings are 
more air ‑tight as compared with the old ones, 
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due to technological differences in construction. 
Regardless of the above speculations, this obser‑
vation needs to be confirmed in further research.
Our study has one potentially significant lim‑
itation, namely, the eligibility assessment for 
spirometry was based on symptom/risk factor 
analysis score rather than random. However, 
the effect of these limitations is minimized by 
a large (relative and absolute) sample size and 
very broad selection criteria for spirometry (spi‑
rometry was offered to more than 50% of par‑
ticipants). To exclude possible overestimation 
of CB prevalence in a local population with nor‑
mal lung function, a conservative approach was 
used, assuming that the proportion of COPD pa‑
tients in the target population is similar to that 
in a sample with spirometry data available. Thus, 
we can state with a high degree of confidence 
that the prevalence of CB symptoms in individ‑
uals without COPD is at least as high as estimat‑
ed in our study. The strengths of our study in‑
clude a large sample size (including the major‑
ity of the target population) and high ‑quality 
spirometry data. It should also be stressed that 
these results apply to a population over 40 years 
old. Although the available data suggest that CB 
symptoms are also common in younger people,5 
the prevalence and correlations of CB in those 
under 40 years old may be significantly differ‑
ent from those reported here.
In conclusion, we demonstrated that in a pop‑
ulation aged 40 years or older without COPD, CB 
is a common yet often undiagnosed condition as‑
sociated with more dyspnea regardless of lung 
function and comorbidities.
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